NCT06931626View on ClinicalTrials.gov

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

February 28, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

NMS-03305293

Route of administration: Oral

DRUG

Temozolomide

Route of administration: Oral Commercially available Temozolomide

Trial Locations (1)

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

Sponsors
All Listed Sponsors
lead

Nerviano Medical Sciences

INDUSTRY

NCT06931626 - Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter